Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure–Function Relationships and Molecular Recognition

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2005-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/01.ATV.0000168421.13467.82PMID 15860736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases

  2005cited by this paper
• The gamma-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding.

  2005cited by this paper
• PAR1 Cleavage and Signaling in Response to Activated Protein C and Thrombin*

  2005cited by this paper
• Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation.

  2004cited by this paper
• Current understanding of disseminated intravascular coagulation

  2004cited by this paper
• Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies

  2004cited by this paper
• Thrombin-activatable fibrinolysis inhibitor.

  2004cited by this paper
• Functional properties of recombinant factor V mutated in a potential calcium-binding site.

  2004cited by this paper
• Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va

  2004cited by this paper
• The C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells*

  2004cited by this paper
• Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?

  2004cited by this paper
• New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology

  2004cited by this paper
• Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3.

  2004cited by this paper
• Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C

  2004cited by this paper
• Interactions between the innate immune and blood coagulation systems

  2004cited by this paper
• Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.

  2004cited by this paper
• The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function

  2004cited by this paper
• Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.

  2004cited by this paper
• The Fourth Epidermal Growth Factor-like Domain of Thrombomodulin Interacts with the Basic Exosite of Protein C*

  2003cited by this paper
• Congenital and acquired activated protein C resistance.

  2003cited by this paper
• Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor.

  2003cited by this paper
• Thrombin interactions.

  2003cited by this paper
• Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective

  2003cited by this paper
• Thrombomodulin

  2003cited by this paper
• Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.

  2003cited by this paper
• Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C

  2003cited by this paper
• Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1.

  2003cited by this paper
• Factor V: a combination of Dr Jekyll and Mr Hyde.

  2003cited by this paper
• The discovery of activated protein C resistance

  2003cited by this paper
• The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis

  2003cited by this paper
• Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells

  2003cited by this paper
• Importance of Protein S and Phospholipid for Activated Protein C-mediated Cleavages in Factor Va*

  2003cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

  2003cited by this paper
• Death in the ICU: feelings of those left behind.

  2003cited by this paper
• The enigma of sepsis.

  2003cited by this paper
• Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice

  2003cited by this paper
• The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways

  2002cited by this paper
• Factor V and Thrombotic Disease: Description of a Janus-Faced Protein

  2002cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002cited by this paper
• Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.

  2002cited by this paper
• Defining the Factor Xa-binding Site on Factor Va by Site-directed Glycosylation*

  2002cited by this paper
• HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY 3-Dimensional structure of membrane-bound coagulation factor VIII : modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography

  2002cited by this paper
• Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells

  2002cited by this paper
• Crystal Structure of a C-terminal Fragment of Growth Arrest-specific Protein Gas6

  2002cited by this paper
• Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-binding and von Willebrand Factor-binding Motifs*

  2002cited by this paper
• Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells1

  2002cited by this paper
• The Crystal Structure of the Endothelial Protein C Receptor and a Bound Phospholipid*

  2002cited by this paper
• Identification of a binding site for blood coagulation factor Xa on the heavy chain of factor Va. Amino acid residues 323-331 of factor V represent an interactive site for activated factor X.

  2002cited by this paper
• Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C*

  2002cited by this paper
• Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C

  2002cited by this paper
• Science review: Role of coagulation protease cascades in sepsis

  2002cited by this paper
• Three‐dimensional model of the SHBG‐like region of anticoagulant protein S: New structure–function insights

  2001cited by this paper
• Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis*

  2001cited by this paper
• Role of thrombin signalling in platelets in haemostasis and thrombosis

  2001cited by this paper
• Tissue Factor: An Enzyme Cofactor and a True Receptor

  2001cited by this paper
• Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va*

  2001cited by this paper
• Endothelial cell protein C receptor plays an important role in protein C activation in vivo.

  2001cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke

  2001cited by this paper
• Localization of a Hydrophobic Binding Site for Anticoagulant Protein S on the β-Chain of Complement Regulator C4b-binding Protein*

  2001cited by this paper
• Structural and Energetic Characteristics of the Heparin-binding Site in Antithrombotic Protein C*

  2001cited by this paper
• The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites.

  2000cited by this paper
• The Endothelial Cell Protein C Receptor

  2000cited by this paper
• The protein C pathway

  2000cited by this paper
• The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.

  2000cited by this paper
• Platelets.

  2000cited by this paper
• Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis.

  2000cited by this paper
• The Second Laminin G-type Domain of Protein S Is Indispensable for Expression of Full Cofactor Activity in Activated Protein C-catalysed Inactivation of Factor Va and Factor VIIIa

  2000cited by this paper
• Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C

  2000cited by this paper
• Structural basis for the anticoagulant activity of the thrombin–thrombomodulin complex

  2000cited by this paper
• Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex

  2000cited by this paper
• Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.

  1999cited by this paper
• Structure of the C2 domain of human factor VIII at 1.5 Å resolution

  1999cited by this paper
• Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.

  1999cited by this paper
• Regulation of Factor VIIIa in the Intrinsic Factor Xase

  1999cited by this paper
• Venous thrombosis: a multicausal disease.

  1999cited by this paper
• Crystal structures of the membrane-binding C2 domain of human coagulation factor V

  1999cited by this paper
• Probing the activation of protein C by the thrombin‐thrombomodulin complex using structural analysis, site‐directed mutagenesis, and computer modeling

  1999cited by this paper
• The life cycle of coagulation factor VIII in view of its structure and function.

  1998cited by this paper
• The C-terminal Region of the Factor V B-domain Is Crucial for the Anticoagulant Activity of Factor V*

  1998cited by this paper
• Structural investigation of the A domains of human blood coagulation factor V by molecular modeling

  1998cited by this paper
• Molecular Models for the two Discoidin Domains of Human Blood Coagulation Factor V

  1998cited by this paper
• Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains.

  1998cited by this paper
• A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.

  1997cited by this paper
• Activated Protein C Cleavage of Factor Va Leads to Dissociation of the A2 Domain*

  1997cited by this paper
• A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: From biostructural pathology to specie

  1997cited by this paper
• A single genetic origin for a common Caucasian risk factor for venous thrombosis.

  1997cited by this paper
• Binding sites for blood coagulation factor Xa and protein S involving residues 493–506 in factor Va

  1996cited by this paper
• Mutation of Protease Domain Residues Lys37-39 in Human Protein C Inhibits Activation by the Thrombomodulin-Thrombin Complex without Affecting Activation by Free Thrombin*

  1996cited by this paper
• Factor V Enhances the Cofactor Function of Protein S in the APC-Mediated Inactivation of Factor VIII: Influence of the Factor VR506Q Mutation

  1996cited by this paper
• The 2.8 A crystal structure of Gla‐domainless activated protein C.

  1996cited by this paper
• The protein C anticoagulant system

  1996cited by this paper
• Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*)

  1995cited by this paper
• Effects of Protein S and Factor Xa on Peptide Bond Cleavages during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*)

  1995cited by this paper
• Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli.

  1995cited by this paper
• Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.

  1994cited by this paper
• Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.

  1994cited by this paper
• Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide.

  1994cited by this paper
• Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: modulation of effects on CD11b and CD14 but not CD25 or CD54 induction.

  1993cited by this paper
• Baboon model of Escherichia coli sepsis: description of its four stages and the role of tumor necrosis factor, tissue factors, and the protein C system in septic shock.

  1991cited by this paper

• Clinical, Molecular and Bioinformatic Study of Common Thrombophilia Mutation Factor V Leiden.

  2026cites this paper
• Clinical, Molecular, and Bioinformatic Study of Common Thrombophilia Mutation Factor V Leiden.

  2026cites this paper
• Anticoagulants: From chance discovery to structure-based design.

  2025cites this paper
• Serum proteomic correlates of mental health symptoms in a representative UK population sample

  2025cites this paper
• Venous thrombosis unchained: Pandora’s box of noninflammatory mechanisms

  2025cites this paper
• Coagulation Profiles Among Combined Oral Contraceptive User and Non-User Women Attending at Family Guidance Association of Ethiopia, Jigjiga Medium Clinic: A Comparative Cross-Sectional Study

  2025cites this paper
• Stochastic resonance represents one of the mechanisms that trigger protein ligand unbinding.

  2025cites this paper
• Phagocytic clearance of targeted cells with a synthetic ligand.

  2025cites this paper
• Hemocompatibility of cyclodextrin-coated magnetic nanoparticles under uremic conditions.

  2025cites this paper
• Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties

  2025cites this paper
• Haemophilia.

  2025cites this paper
• Covalent Organic Framework‐Based Porous Anticoagulant Materials for Extracorporeal Blood Circulation

  2025cites this paper
• Heritable genetic Variability in ovarian Tumours: Exploring venous thromboembolism susceptibility and cancer prognosis in a Hospital-Based study.

  2025cites this paper
• Distinct pathogenic mechanisms underlying two protein C variants (p.Arg211Gln and p.Val367Met) in a thrombophilic family: integrated functional and structural analyses

  2025cites this paper
• Endothelium-Dependent Protein C Activation in Hereditary Protein C Deficiency

  2025cites this paper
• WE-thrombin induces cytoprotective signaling in endothelial cells by cleavage of Arg46 of protease-activated receptor 1.

  2025cites this paper
• Impact of nonsynonymous single nucleotide polymorphisms in PROCR gene on protein stability and thrombotic risk: a molecular dynamic approach

  2025cites this paper
• The preclinical profile of SerpinPC: a potential new treatment for hemophilia

  2025cites this paper
• The role of factor V in trauma-induced coagulopathy: an observational and experimental study

  2025cites this paper
• Integrated Management of Stroke Risk in Brain Cancer: Insights from the Tumoral Bleeding Classification System and CanStroke Protocol

  2025cites this paper
• A novel rapid single-integrated immunoassay for plasma thrombomodulin: analytical performance and multi-center clinical validation.

  2025cites this paper
• Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time

  2024cites this paper
• Effect of Uremic Toxins and Methoxy-PEO Chain Density on Plasma Protein Adsorption.

  2024cites this paper
• Thrombophilia Screening: Not So Straightforward

  2024cites this paper
• The Association between Coagulation and Atrial Fibrillation

  2024cites this paper
• Advances in biopharmaceutical products for hemophilia

  2024cites this paper
• Transcriptomic analysis of the effect of remote ischaemic conditioning in an animal model of necrotising enterocolitis

  2024cites this paper
• Managing Temporomandibular Joint Ankylosis Concurrent With Extrahepatic Portal Vein Obstruction: A Report of a Rare Case and Literature Review Investigating the Hypercoagulability Link

  2024cites this paper
• Decoding the Nexus: Cellular and Molecular Mechanisms Linking Stroke and Neurotoxic Microenvironments in Brain Cancer Patients

  2024cites this paper
• Effect of hydroxy-PEO chain density and uremic toxins on plasma protein adsorption

  2024cites this paper
• Validation for the function of protein C in mouse models

  2024cites this paper
• Endothelial Protein C Receptor and Its Impact on Rheumatic Disease

  2024cites this paper
• Platelets at the intersection of inflammation and coagulation in the APC‐mediated response to myocardial ischemia/reperfusion injury

  2024cites this paper
• The natural anticoagulant protein S; hemostatic functions and deficiency

  2024cites this paper
• Multifocal osteonecrosis due to the synergistic impact of inherited thrombophilia, autoimmunity and pregnancy: a case report.

  2024cites this paper
• Role of TAM Receptors in Antimalarial Humoral Immune Response

  2024cites this paper
• Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 FAERS data.

  2024cites this paper
• COAGULATION AND ANTICOAGULATION PARAMETERS IN MULTIPLE SCLEROSIS PATIENTS WITH AND WITHOUT COVID-19

  2024cites this paper
• Tissue factor-dependent colitogenic CD4+ T cell thrombogenicity is regulated by activated protein C signalling

  2024cites this paper
• Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems

  2024cites this paper
• Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates

  2024cites this paper
• Thrombomodulin Switches Signaling and Protease-Activated Receptor 1 Cleavage Specificity of Thrombin

  2024cites this paper
• Membrane-Dependent Reactions of Blood Coagulation: Classical View and State-of-the-Art Concepts

  2024cites this paper
• Association between Driving Pressure, Systemic Inflammation and Non-pulmonary Organ Dysfunction in Patients with Acute Respiratory Distress Syndrome, a Prospective Pathophysiological Study.

  2024cites this paper
• Cytoprotective E-WE thrombin reduces disease severity in a murine model of relapsing-remitting multiple sclerosis.

  2023cites this paper
• Evaluation of protein C and S levels in patients with COVID-19 infection and their relation to disease severity

  2023cites this paper
• Soluble endothelial protein C receptor is an independent predictor of venous thromboembolism after severe injury: Secondary analysis of a prospective cohort study.

  2023cites this paper
• NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V

  2023cites this paper
• Variation in presepsin and thrombomodulin levels for predicting COVID-19 mortality

  2023cites this paper
• Natural anticoagulant discovery, the gift that keeps on giving: finding FV-Short.

  2023cites this paper
• Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.

  2023cites this paper
• The Role of Tissue Factor In Signaling Pathways of Pathological Conditions and Angiogenesis.

  2023cites this paper
• The Crossroads of the Coagulation System and the Immune System: Interactions and Connections

  2023cites this paper
• The pathogenesis of obstetric APS: a 2023 update.

  2023cites this paper
• Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study.

  2023cites this paper
• Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer

  2023cites this paper
• Therapeutic targeting of the functionally elusive TAM receptor family

  2023cites this paper
• Anticoagulation for cardiopulmonary bypass, Part 2: alternatives and pathological states.

  2023cites this paper
• Recent advances in the role of neutrophils and neutrophil extracellular traps in acute pancreatitis

  2023cites this paper
• To clot, or not to clot: The dilemma of hormone treatment options for menopause.

  2022cites this paper
• Significance of altered anticoagulant proteins and D-dimer in cirrhotic portal vein thrombosis: relation to the degree of liver dysfunction

  2022influential citation
• Recommendations from the ICM-VTE: General.

  2022cites this paper
• The role of extracellular histones in COVID‐19

  2022cites this paper
• Plasma levels of thrombin and activated protein C in patients with acute myocardial Infarction: An observational study

  2022cites this paper
• TAM Receptors in the Pathophysiology of Liver Disease

  2022cites this paper
• Assessment of the Level of Protein C in Hospitalized Iraqi Patients with COVID-19 and its Correlation with Hematological and Inflammatory Markers

  2022cites this paper
• Molecular View into Preferential Binding of the Factor VII Gla Domain to Phosphatidic Acid.

  2022cites this paper
• Protein C system in preterm babies with chronic lung disease: Prospective study.

  2022cites this paper
• Extracellular DNA Traps: Origin, Function and Implications for Anti-Cancer Therapies

  2022cites this paper
• Serum proteomics of severe fever with thrombocytopenia syndrome patients

  2022cites this paper
• Identification of Di/Tripeptide(s) With Osteoblasts Proliferation Stimulation Abilities of Yak Bone Collagen by in silico Screening and Molecular Docking

  2022cites this paper
• An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection

  2022cites this paper
• Impact of Off-Label Under-Dose Direct Oral Anticoagulant on Coagulation and Fibrinolytic Markers in Patients with Atrial Fibrillation

  2022cites this paper
• When Two Maladies Meet: Disease Burden and Pathophysiology of Stroke in Cancer

  2022cites this paper
• Protein C Pathway in Paediatric and Neonatal Sepsis

  2022cites this paper
• The role of thrombin in haemostasis

  2022cites this paper
• Novel Mechanisms of Anthracycline-Induced Cardiovascular Toxicity: A Focus on Thrombosis, Cardiac Atrophy, and Programmed Cell Death

  2022cites this paper
• 2LAYOUT-Review Article-dr fahmy copy

  2021cites this paper
• Vitamin K Effects on Gas6 and Soluble Axl Receptors in Intensive Care Patients: An Observational Screening Study

  2021cites this paper
• Signaling pathways and intervention therapies in sepsis

  2021cites this paper
• The impact of activated protein C resistance on the patency of arteriovenous grafts for hemodialysis access

  2021cites this paper
• Disseminated intravascular coagulation and its immune mechanisms

  2021cites this paper
• The cardiac molecular setting of metabolic syndrome in pigs reveals disease susceptibility and suggests mechanisms that exacerbate COVID-19 outcomes in patients

  2021cites this paper
• Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH

  2021cites this paper
• PC Deficiency Testing: Thrombin-Thrombomodulin as PC Activator and Aptamer-Based Enzyme Capturing Increase Diagnostic Accuracy

  2021cites this paper
• Investigation of the Molecular Mechanism of Coagulopathy in Severe and Critical Patients With COVID-19

  2021cites this paper
• Thrombomodulin in skin diseases

  2021influential citation
• Comparative Analysis of the Hemostasiological Profile in Sheep and Patients with Cardiovascular Pathology as the Basis for Predicting Thrombotic Risks During Preclinical Tests of Vascular Prostheses

  2021cites this paper
• Regulation and Dysregulation of Thrombin Activity

  2021cites this paper
• The beneficial therapeutic effects of statins, angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers on protein-C and protein-S activities in Egyptian patients with type-2 diabetes mellitus

  2021cites this paper
• Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells

  2021cites this paper
• Osteonecrosis of the Femoral Head in Patients with Hypercoagulability—From Pathophysiology to Therapeutic Implications

  2021cites this paper
• Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia

  2021cites this paper
• Portal Vein Thrombosis following Total Colectomy due to Colonic Inertia: A Case Report and Evaluation of Risk Factors

  2021cites this paper
• Effects of IgG from the serum of ischemic stroke patients on hemostasis

  2021cites this paper
• Clinical and Molecular Study of Common Thrombophilia Mutation Prothrombin G20210A.

  2021cites this paper
• Linking clotting and autoimmunity

  2021cites this paper
• Features of hemostasis disorders in patients with CKD VD stage and their relationship with the course of the disease

  2020cites this paper
• Neuroprotective Effects of Activated Protein C Involve the PARP/AIF Pathway against Oxygen-Glucose Deprivation in SH-SY5Y Cells

  2020cites this paper
• An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

  2020cites this paper